PL2146745T3 - Pięcioswoiste przeciwciało - Google Patents

Pięcioswoiste przeciwciało

Info

Publication number: PL2146745T3
Authority: PL; Poland
Prior art keywords: penta; specific antibody; antibody; specific
Prior art date: 2007-04-17

Application number

PL08745931T

Other languages

English (en)

Inventor

Stephanie Jane Clegg

Eric Dobrzynski

Jonathan H Ellis

Volker Germaschewski

Alexis Paul Godillot

Zdenka Ludmila Jonak

Alan P Lewis

John R White

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-17

Filing date

2008-04-16

Publication date

2015-11-30

2008-04-16 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2015-11-30 Publication of PL2146745T3 publication Critical patent/PL2146745T3/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Vascular Medicine (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Diabetes (AREA)

PL08745931T 2007-04-17 2008-04-16 Pięcioswoiste przeciwciało PL2146745T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US91222907P	2007-04-17	2007-04-17
US4413208P	2008-04-11	2008-04-11
PCT/US2008/060424 WO2008130969A2 (en)	2007-04-17	2008-04-16	Novel compounds
EP08745931.9A EP2146745B1 (en)	2007-04-17	2008-04-16	penta-specific antibody

Publications (1)

Publication Number	Publication Date
PL2146745T3 true PL2146745T3 (pl)	2015-11-30

Family

ID=39872910

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL08745931T PL2146745T3 (pl)	2007-04-17	2008-04-16	Pięcioswoiste przeciwciało

Country Status (29)

Country	Link
US (3)	US8496932B2 (pl)
EP (1)	EP2146745B1 (pl)
JP (1)	JP5441885B2 (pl)
KR (1)	KR101560841B1 (pl)
CN (1)	CN101687035B (pl)
AU (1)	AU2008243049B2 (pl)
BR (1)	BRPI0810250A8 (pl)
CA (1)	CA2684626C (pl)
CL (1)	CL2008001071A1 (pl)
CO (1)	CO6251323A2 (pl)
CR (1)	CR11116A (pl)
CY (1)	CY1116671T1 (pl)
DK (1)	DK2146745T3 (pl)
DO (1)	DOP2009000236A (pl)
EA (1)	EA024621B1 (pl)
ES (1)	ES2547475T3 (pl)
HR (1)	HRP20150937T1 (pl)
HU (1)	HUE027584T2 (pl)
IL (1)	IL201440A (pl)
MA (1)	MA31310B1 (pl)
MX (1)	MX2009011153A (pl)
MY (1)	MY150525A (pl)
NZ (1)	NZ580239A (pl)
PE (1)	PE20090302A1 (pl)
PL (1)	PL2146745T3 (pl)
PT (1)	PT2146745E (pl)
SI (1)	SI2146745T1 (pl)
TW (1)	TWI473815B (pl)
WO (1)	WO2008130969A2 (pl)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IN2014DN10515A (pl)	2006-03-31	2015-08-21	Chugai Pharmaceutical Co Ltd
MX336725B (es)	2007-09-26	2016-01-28	Chugai Pharmaceutical Co Ltd	Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
TWI700293B (zh)	2008-04-11	2020-08-01	日商中外製藥股份有限公司	重複結合複數個抗原的抗體
US8324352B2 (en)	2009-12-07	2012-12-04	Decimmune Therapeutics, Inc.	Anti-inflammatory antibodies and uses therefor
EP2534256A4 (en) *	2010-02-09	2013-07-24	Glaxosmithkline Llc	NEW USES
KR102568454B1 (ko)	2010-11-30	2023-08-18	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
JP6211597B2 (ja) *	2012-05-01	2017-10-11	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅＬＬＣ	新規抗体
EP3597747B1 (en)	2012-08-24	2023-03-15	Chugai Seiyaku Kabushiki Kaisha	Mouse fcgammarii-specific fc antibody
TWI855488B (zh)	2012-08-24	2024-09-11	日商中外製藥股份有限公司	FcγRIIb特異性Fc區域變異體
HK1220207A1 (zh)	2013-03-12	2017-04-28	Decimmune Therapeutics Inc.	人源化抗n2抗体
US9290570B2 (en)	2013-03-15	2016-03-22	Eli Lilly And Company	Pan-ELR+ CXC Chemokine Antibodies
TWI612059B (zh) *	2013-03-15	2018-01-21	美國禮來大藥廠	泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體
AU2014250434B2 (en)	2013-04-02	2019-08-08	Chugai Seiyaku Kabushiki Kaisha	Fc region variant
EP2796875B8 (en) *	2013-04-23	2020-11-25	Albert-Ludwigs-Universität Freiburg	Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis
AU2014267171A1 (en) *	2013-05-17	2015-12-10	Centre National De La Recherche Scientifique (Cnrs)	Anti-CXCL1, CXCL7 and CXCL8 antibodies and their applications
TWI656133B (zh)	2014-12-19	2019-04-11	日商中外製藥股份有限公司	抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
WO2016125495A1 (en)	2015-02-05	2016-08-11	Chugai Seiyaku Kabushiki Kaisha	Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
WO2017110981A1 (en)	2015-12-25	2017-06-29	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
CN109689099B (zh)	2016-08-05	2023-02-28	中外制药株式会社	用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en)	2016-09-16	2018-04-27	Chugai Pharmaceutical Co Ltd	Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
WO2019036605A2 (en) *	2017-08-17	2019-02-21	Massachusetts Institute Of Technology	MULTIPLE SPECIFICITY BINDING AGENTS OF CXC CHEMOKINES AND USES THEREOF
US11525002B2 (en)	2017-10-11	2022-12-13	Board Of Regents, The University Of Texas System	Human PD-L1 antibodies and methods of use therefor
IL277375B2 (en)	2018-03-15	2025-08-01	Chugai Pharmaceutical Co Ltd	Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
EP3768726B1 (en)	2018-03-23	2024-10-30	Board of Regents, The University of Texas System	Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor
JP7390301B2 (ja)	2018-03-23	2023-12-01	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	ヒトｐｄ－ｌ２抗体およびその使用方法
JP7514765B2 (ja) *	2018-03-23	2024-07-11	ボードオブリージェンツ，ザユニバーシティオブテキサスシステム	ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体およびその使用方法
TWI884192B (zh) *	2019-12-05	2025-05-21	美商西健公司	抗αＶβ６抗體及抗體-藥物結合物
TW202206457A (zh) *	2020-04-24	2022-02-16	美商美國禮來大藥廠	用於治療呼吸疾病之泛elr+ cxc趨化因子抗體
US20220080044A1 (en) *	2020-09-14	2022-03-17	National Yang-Ming University	Method for preventing or treating peripheral arterial occlusive disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE913192A1 (en)	1990-09-12	1992-02-25	Scripps Research Inst	Active site of interleukin-8: polypeptide analogs and¹antibodies
US6448379B1 (en) *	1993-09-14	2002-09-10	Chiron Corporation	IL8 inhibitors
DK0833911T3 (da) *	1995-06-07	2004-08-30	Ortho Mcneil Pharm Inc	CDR-transplanterede anti-vævsfaktorantistoffer og fremgangsmåder til anvendelse deraf
GB0020685D0 (en) *	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
AR030753A1 (es) *	2000-09-25	2003-09-03	Smithkline Beecham Corp	Uso de moduladores-proteina de il-8, groalfa, grobeta, grogamma, nap-2, y ena-78, para tratar infecciones viricas
EE200300179A (et) *	2000-10-13	2003-08-15	Biogen, Inc.	Humaniseeritud LT-ß-R-i vastased antikehad
EP1414860B1 (en)	2001-04-26	2009-12-30	Dako Denmark A/S	Anti-glycated hemoglobin pan-specific monoclonal antibody
US20040022726A1 (en) *	2002-06-03	2004-02-05	Goldenberg David M.	Methods and compositions for intravesical therapy of bladder cancer
ES2373947T3 (es) *	2002-12-16	2012-02-10	Genmab A/S	Anticuerpos monoclonales humanos contra interleucina 8 (il-8).
WO2004060919A1 (ja) *	2002-12-26	2004-07-22	Chugai Seiyaku Kabushiki Kaisha	ヘテロ受容体に対するアゴニスト抗体
EP1610818A4 (en) *	2004-03-03	2007-09-19	Millennium Pharm Inc	MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
WO2006074399A2 (en) *	2005-01-05	2006-07-13	Biogen Idec Ma Inc.	Multispecific binding molecules comprising connecting peptides
US20070014720A1 (en) *	2005-06-02	2007-01-18	Gadi Gazit-Bornstein	Antibodies directed to CD20 and uses thereof
PT2100618E (pt) *	2005-06-17	2014-04-07	Philadelphia Health & Educatio	Um anticorpo anti-pdgfr-alfa para o tratamento de cancro ósseo metastático
GB0519398D0 (en) *	2005-09-23	2005-11-02	Antisoma Plc	Biological materials and uses thereof
US20070161089A1 (en) *	2005-11-08	2007-07-12	Genentech, Inc.	Method of Producing Pan-Specific Antibodies
US8454960B2 (en) *	2008-01-03	2013-06-04	The Scripps Research Institute	Multispecific antibody targeting and multivalency through modular recognition domains

2008
- 2008-04-15 CL CL2008001071A patent/CL2008001071A1/es unknown
- 2008-04-16 TW TW97113788A patent/TWI473815B/zh not_active IP Right Cessation
- 2008-04-16 HU HUE08745931A patent/HUE027584T2/en unknown
- 2008-04-16 MX MX2009011153A patent/MX2009011153A/es active IP Right Grant
- 2008-04-16 AU AU2008243049A patent/AU2008243049B2/en not_active Ceased
- 2008-04-16 CA CA2684626A patent/CA2684626C/en not_active Expired - Fee Related
- 2008-04-16 JP JP2010504204A patent/JP5441885B2/ja not_active Expired - Fee Related
- 2008-04-16 NZ NZ580239A patent/NZ580239A/en not_active IP Right Cessation
- 2008-04-16 WO PCT/US2008/060424 patent/WO2008130969A2/en not_active Ceased
- 2008-04-16 KR KR1020097023814A patent/KR101560841B1/ko not_active Expired - Fee Related
- 2008-04-16 PL PL08745931T patent/PL2146745T3/pl unknown
- 2008-04-16 BR BRPI0810250A patent/BRPI0810250A8/pt not_active Application Discontinuation
- 2008-04-16 EA EA200970954A patent/EA024621B1/ru not_active IP Right Cessation
- 2008-04-16 DK DK08745931.9T patent/DK2146745T3/en active
- 2008-04-16 CN CN2008800205593A patent/CN101687035B/zh not_active Expired - Fee Related
- 2008-04-16 MY MYPI20094336 patent/MY150525A/en unknown
- 2008-04-16 US US12/596,262 patent/US8496932B2/en not_active Expired - Fee Related
- 2008-04-16 SI SI200831489T patent/SI2146745T1/sl unknown
- 2008-04-16 HR HRP20150937TT patent/HRP20150937T1/hr unknown
- 2008-04-16 PT PT87459319T patent/PT2146745E/pt unknown
- 2008-04-16 EP EP08745931.9A patent/EP2146745B1/en not_active Not-in-force
- 2008-04-16 PE PE2008000664A patent/PE20090302A1/es not_active Application Discontinuation
- 2008-04-16 US US12/103,761 patent/US20080262203A1/en not_active Abandoned
- 2008-04-16 ES ES08745931.9T patent/ES2547475T3/es active Active
2009
- 2009-10-08 DO DO2009000236A patent/DOP2009000236A/es unknown
- 2009-10-11 IL IL201440A patent/IL201440A/en not_active IP Right Cessation
- 2009-10-15 MA MA32279A patent/MA31310B1/fr unknown
- 2009-10-19 CO CO09116578A patent/CO6251323A2/es active IP Right Grant
- 2009-11-17 CR CR11116A patent/CR11116A/es unknown
2013
- 2013-06-26 US US13/927,352 patent/US8828384B2/en not_active Expired - Fee Related
2015
- 2015-09-01 CY CY20151100768T patent/CY1116671T1/el unknown

Also Published As

Publication number	Publication date
IL201440A0 (en)	2010-06-16
DOP2009000236A (es)	2009-11-15
JP5441885B2 (ja)	2014-03-12
ES2547475T3 (es)	2015-10-06
CN101687035B (zh)	2013-06-12
CL2008001071A1 (es)	2009-05-22
TWI473815B (zh)	2015-02-21
EA024621B1 (ru)	2016-10-31
EP2146745B1 (en)	2015-06-17
HRP20150937T1 (hr)	2015-10-09
US20080262203A1 (en)	2008-10-23
EP2146745A2 (en)	2010-01-27
CR11116A (es)	2010-03-22
MX2009011153A (es)	2009-10-30
US8496932B2 (en)	2013-07-30
CY1116671T1 (el)	2017-03-15
WO2008130969A2 (en)	2008-10-30
DK2146745T3 (en)	2015-09-14
EA200970954A1 (ru)	2010-08-30
CN101687035A (zh)	2010-03-31
SI2146745T1 (sl)	2015-10-30
AU2008243049A1 (en)	2008-10-30
BRPI0810250A2 (pt)	2014-10-14
HUE027584T2 (en)	2016-11-28
JP2010524469A (ja)	2010-07-22
AU2008243049B2 (en)	2011-04-21
KR101560841B1 (ko)	2015-11-11
HK1136970A1 (en)	2010-07-16
CA2684626A1 (en)	2008-10-30
WO2008130969A3 (en)	2008-12-18
IL201440A (en)	2016-08-31
EP2146745A4 (en)	2011-11-30
CA2684626C (en)	2014-11-04
BRPI0810250A8 (pt)	2017-02-21
PT2146745E (pt)	2015-10-14
CO6251323A2 (es)	2011-02-21
US8828384B2 (en)	2014-09-09
US20140010807A1 (en)	2014-01-09
NZ580239A (en)	2012-07-27
MA31310B1 (fr)	2010-04-01
TW200906855A (en)	2009-02-16
KR20100020946A (ko)	2010-02-23
PE20090302A1 (es)	2009-04-03
US20110229475A1 (en)	2011-09-22
MY150525A (en)	2014-01-30

Publication	Publication Date	Title
EP2138576A4 (en)	2011-02-23	ANTI-CLAUDIN-4 ANTIBODY
PL2146745T3 (pl)	2015-11-30	Pięcioswoiste przeciwciało
GB0708002D0 (en)	2007-06-06	Antibodies
SI2200700T1 (sl)	2016-04-29	Nova protitelesa
ZA201102119B (en)	2011-12-28	Improved antibody libraies
ZA201002422B (en)	2014-06-25	Modified antibody constant region
EP2077859A4 (en)	2010-11-24	ANTIBODY FORMULATION
IL206103A0 (en)	2010-11-30	Antibody formulation
GB0821100D0 (en)	2008-12-24	Antibodies
IL202648A0 (en)	2011-08-01	Antibody formulations
IL202950A0 (en)	2011-08-01	Antibody formulations
ZA201002275B (en)	2011-06-29	Il-23 antibodies
IL205073A0 (en)	2010-11-30	Anti-bst2 antibody
EP2173163A4 (en)	2010-12-08	ANTIBODY FORMULATIONS
GB0718737D0 (en)	2007-11-07	Antibodies
PL2011869T3 (pl)	2014-11-28	Nowe przeciwciało anty-CD98
IL207581A0 (en)	2010-12-30	Anti-tyrp1 antibodies
GB0702888D0 (en)	2007-03-28	Novel Antibodies
GB0615662D0 (en)	2006-09-13	Antibody
ZA201007976B (en)	2012-02-29	Anti-pirb antibodies
GB0818356D0 (en)	2008-11-12	Antibodies
GB0911770D0 (en)	2009-08-19	Antibody
EP2167635A4 (en)	2010-06-30	ANTIBODY FORMULATIONS
GB0724185D0 (en)	2008-01-23	Antibodies
GB0817621D0 (en)	2008-11-05	Antibody